Sientra (SIEN) Stock Price, News & Analysis

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sientra in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" SIEN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SIEN, but not buy additional shares or sell existing shares.
View SIEN analyst ratings or view top-rated stocks.

Sientra, Inc. (NASDAQ:SIEN) posted its earnings results on Wednesday, November, 10th. The medical instruments supplier reported ($0.80) EPS for the quarter, topping the consensus estimate of ($2.60) by $1.80. The medical instruments supplier had revenue of $19.62 million for the quarter, compared to the consensus estimate of $18.10 million. During the same quarter last year, the firm earned ($3.30) EPS.

Shares of Sientra reverse split on Monday, January 23rd 2023. The 1-10 reverse split was announced on Monday, January 23rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Sientra investors own include Rigel Pharmaceuticals (RIGL), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), ADMA Biologics (ADMA), Miragen Therapeutics (MGEN), Corbus Pharmaceuticals (CRBP), Dynavax Technologies (DVAX), Micron Technology (MU) and Novavax (NVAX).